{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT03546829",
            "orgStudyIdInfo": {
                "id": "UPCC 08517"
            },
            "secondaryIdInfos": [
                {
                    "id": "827551",
                    "type": "OTHER",
                    "domain": "University of Pennsylvania IRB"
                }
            ],
            "organization": {
                "fullName": "Abramson Cancer Center at Penn Medicine",
                "class": "OTHER"
            },
            "briefTitle": "Safety Trial of Antimicrobial Therapy and Precision Radiation Therapy in Patients With Oligoprogressive Non-small Cell Lung Cancer",
            "officialTitle": "Safety Trial of Antimicrobial Therapy and Precision Radiation Therapy in Patients With Oligoprogressive Non-small Cell Lung Cancer",
            "therapeuticArea": [
                "Oncology and Hematology"
            ],
            "study": "safety-trial-of-antimicrobial-therapy-and-precision-radiation-therapy-in-patients-with-oligoprogressive-non-small-cell-lung-cancer"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-07",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2019-03-05",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2026-12-31",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2027-12-31",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2018-05-23",
            "studyFirstSubmitQcDate": "2018-05-23",
            "studyFirstPostDateStruct": {
                "date": "2018-06-06",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-07-25",
            "lastUpdatePostDateStruct": {
                "date": "2024-07-30",
                "type": "ESTIMATED"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Abramson Cancer Center at Penn Medicine",
                "class": "OTHER"
            }
        },
        "oversightModule": {
            "oversightHasDmc": false,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false,
            "isUsExport": false
        },
        "descriptionModule": {
            "briefSummary": "The first phase of this study was an open label, randomized pilot study. Enrollment for this phase is now complete.\n\nThe second phase is a single arm phase 1 safety study. Patients planned to undergo precision hypofractionated radiation to all sites of oligoprogression will receive vancomycin for 1 week before RT and for 1 month after start of RT, and asked to provide stool and blood samples as outlined in the Safety Trial study table."
        },
        "conditionsModule": {
            "conditions": [
                "Early Stage Non-Small Cell Lung Cancer"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE1"
            ],
            "designInfo": {
                "allocation": "NA",
                "interventionModel": "SINGLE_GROUP",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 10,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Arm 1 - Experimental",
                    "type": "EXPERIMENTAL",
                    "description": "Patients planned to undergo precision hypofractionated radiation to all sites of oligoprogression will receive vancomycin for 1 week before RT and for 1 month after start of RT, and asked to provide stool and blood samples as outlined in the Safety Trial study table.",
                    "interventionNames": [
                        "Drug: Vancomycin",
                        "Radiation: Precision hypofractionated radiation"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "Vancomycin",
                    "description": "125 mg, 4x daily for 5 weeks",
                    "armGroupLabels": [
                        "Arm 1 - Experimental"
                    ]
                },
                {
                    "type": "RADIATION",
                    "name": "Precision hypofractionated radiation",
                    "description": "Patients planned to undergo precision hypofractionated radiation to all sites of oligoprogression and will receive vancomycin for 1 week before RT and for 1 month after start of RT, and asked to provide stool and blood samples as outlined in the Safety Trial study table.",
                    "armGroupLabels": [
                        "Arm 1 - Experimental"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Randomized Pilot: Th1 immune response measured by cytokine expression (IFN gamma).",
                    "description": "The primary endpoint is IFN-gamma cytokine expression at Day 30 (+/- 2) collection compared to the pre-radiation level. It will be analyzed using generalized linear mixed models.",
                    "timeFrame": "2 years"
                },
                {
                    "measure": "Randomized Pilot: the safety of the addition of vancomycin to Stereotactic Body Radiotherapy",
                    "description": "The primary safety endpoint is uncontrolled diarrhea, as defined by CTCAE v4.0 \\> or = grade 3 (Increase of \\>=7 stools per day over baseline; incontinence; hospitalization indicated; severe increase in ostomy output compared to baseline; limiting self-care ADL). This will be evaluated during treatment and at 1 month, 3 months, 6 months and 12 months.",
                    "timeFrame": "2 years"
                },
                {
                    "measure": "Safety Trial: the safety of the addition of vancomycin to precision hypofractionated radiation",
                    "description": "Safety Trial: The primary safety endpoint is uncontrolled diarrhea, as defined by CTCAE v5.0 \\> or = grade 3 Increase of \\>=7 stools per day over baseline; hospitalization indicated; severe increase in ostomy output compared to baseline; limiting self care ADL). This will be evaluated weekly during vancomycin use and RT, at 1 month post-vancomycin, 3 months post-vancomycin, 6 months post-vancomycin and 12 months post-vancomycin.",
                    "timeFrame": "3 years"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Randomized Pilot Inclusion\n\n* Patients planned to receive Stereotactic Body Radiotherapy (SBRT) to a biopsy-proven or clinically-suspected NSCLC\n* Age \\>18 years' old\n* Patient capable of giving informed consent\n\nRandomized Pilot Exclusion\n\n* Use of antibiotics, antifungal, antivirals or antiparasitics during the 4 weeks prior to registration\n* Active infection with oral temperature \\>100\u00b0F\n* Use of corticosteroids, methotrexate or immunosuppressive drugs during the 4 weeks prior to registration\n* Use of chemotherapy during the 4 weeks prior to radiotherapy or during radiotherapy. Chemotherapy cannot begin before the collection of the 30-day post treatment sample (S4).\n* Documented history of HIV, HBV or HCV\n* Active uncontrolled gastrointestinal disorders such as inflammatory bowel disease, moderate/severe irritable bowel syndrome, persistent, infectious gastroenteritis, colitis or gastritis, persistent or chronic diarrhea of unknown etiology, Clostridium Difficile infection (within 2 years of lung cancer diagnosis) or Helicobacter Pylori infection (untreated)\n* Major surgery of the GI tract, with the exception of cholecystectomy and appendectomy, in the past five years. Any major bowel resection at any time\n* Patients on anti-diarrheal medications\n* Patients on probiotics\n\nSafety Trial Inclusion\n\n* Patients planned to receive precision hypofractionated radiation (SBRT or an ablative dose of radiation is used if SBRT is not appropriate or if insurance does not approve - i.e. \\> 30 Gy in 10 fraction equivalent) to all sites of oligoprogressive NSCLC who progressed after 1st line systemic therapy which included immunotherapy\n* The number of sites of progression are \\< 5 sites.\n* Age \\>18 years' old\n* Patient capable of giving informed consent\n\nSafety Trial Exclusion\n\n* Evidence of CNS or leptomeningeal disease\n* Use of antibiotics, antifungal, antivirals or antiparasitics during the 4 weeks prior to registration\n* Active infection with oral temperature \\>100\u00b0F\n* Use of corticosteroids, methotrexate or immunosuppressive drugs during the 4 weeks prior to registration\n* Use of chemotherapy during the 4 weeks prior to radiotherapy or during radiotherapy. Chemotherapy cannot begin before the collection of the 30-day post treatment sample (S3).\n* Documented history of HIV, HBV or HCV\n* Active uncontrolled gastrointestinal disorders such as inflammatory bowel disease, moderate/severe irritable bowel syndrome, persistent, infectious gastroenteritis, colitis or gastritis, persistent or chronic diarrhea of unknown etiology, Clostridium Difficile infection (within 2 years of lung cancer diagnosis) or Helicobacter Pylori infection (untreated)\n* Major surgery of the GI tract, with the exception of cholecystectomy and appendectomy, in the past five years. Any major bowel resection at any time\n* Patients on anti-diarrheal medications\n* Use of probiotics during the 4 weeks prior to radiotherapy or during radiotherapy",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Ching Lai",
                    "role": "CONTACT",
                    "phone": "267-250-9244",
                    "email": "ching.lai@pennmedicine.upenn.edu"
                },
                {
                    "name": "RadOnc Clinical Research Unit",
                    "role": "CONTACT",
                    "email": "radonccru@pennmedicine.upenn.edu"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Steven Feigenberg, MD",
                    "affiliation": "University of Pennsylvania",
                    "role": "PRINCIPAL_INVESTIGATOR"
                }
            ],
            "locations": [
                {
                    "facility": "University of Pennsylvania",
                    "status": "RECRUITING",
                    "city": "Philadelphia",
                    "state": "Pennsylvania",
                    "zip": "19104",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Ching Lai",
                            "role": "CONTACT",
                            "phone": "267-250-9244",
                            "email": "ching.lai@pennmedicine.upenn.edu"
                        },
                        {
                            "name": "RadOnc Clinical Research Unit",
                            "role": "CONTACT",
                            "email": "radonccru@pennmedicine.upenn.edu"
                        },
                        {
                            "name": "Steven Feigenberg, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 39.95233,
                        "lon": -75.16379
                    }
                }
            ]
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000008175",
                    "term": "Lung Neoplasms"
                },
                {
                    "id": "D000002289",
                    "term": "Carcinoma, Non-Small-Cell Lung"
                }
            ],
            "ancestors": [
                {
                    "id": "D000012142",
                    "term": "Respiratory Tract Neoplasms"
                },
                {
                    "id": "D000013899",
                    "term": "Thoracic Neoplasms"
                },
                {
                    "id": "D000009371",
                    "term": "Neoplasms by Site"
                },
                {
                    "id": "D000009369",
                    "term": "Neoplasms"
                },
                {
                    "id": "D000008171",
                    "term": "Lung Diseases"
                },
                {
                    "id": "D000012140",
                    "term": "Respiratory Tract Diseases"
                },
                {
                    "id": "D000002283",
                    "term": "Carcinoma, Bronchogenic"
                },
                {
                    "id": "D000001984",
                    "term": "Bronchial Neoplasms"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M5546",
                    "name": "Carcinoma, Non-Small-Cell Lung",
                    "asFound": "Non-small Cell Lung Cancer",
                    "relevance": "HIGH"
                },
                {
                    "id": "M11172",
                    "name": "Lung Neoplasms",
                    "asFound": "Lung Cancer",
                    "relevance": "HIGH"
                },
                {
                    "id": "M5534",
                    "name": "Carcinoma",
                    "relevance": "LOW"
                },
                {
                    "id": "M14979",
                    "name": "Respiratory Tract Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M16658",
                    "name": "Thoracic Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M11168",
                    "name": "Lung Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M14977",
                    "name": "Respiratory Tract Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M5540",
                    "name": "Carcinoma, Bronchogenic",
                    "relevance": "LOW"
                },
                {
                    "id": "M5260",
                    "name": "Bronchial Neoplasms",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC04",
                    "name": "Neoplasms"
                },
                {
                    "abbrev": "BC08",
                    "name": "Respiratory Tract (Lung and Bronchial) Diseases"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                }
            ]
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "D000014640",
                    "term": "Vancomycin"
                }
            ],
            "ancestors": [
                {
                    "id": "D000000900",
                    "term": "Anti-Bacterial Agents"
                },
                {
                    "id": "D000000890",
                    "term": "Anti-Infective Agents"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M17388",
                    "name": "Vancomycin",
                    "asFound": "Evidence",
                    "relevance": "HIGH"
                },
                {
                    "id": "M4222",
                    "name": "Anti-Bacterial Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M4214",
                    "name": "Anti-Infective Agents",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "Infe",
                    "name": "Anti-Infective Agents"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                }
            ]
        }
    },
    "hasResults": false
}